You are here
Disclosure of large shareholdings
Bergen, 24 September 2018 - Myrlid AS, a company controlled by Kjetil Myrlid Aasen, has today, purchased 129,800 subscription rights in PCI Biotech Holding ASA's (“PCI Biotech”) ongoing rights issue. The terms of the subscription rights are described in PCI Biotech's prospectus dated 17 September 2018. As a result of this transaction, Myrlid AS has increased its holding in PCI Biotech to 1,240,000 shares and 725,000 subscriptions rights, or from 4.96%, prior to the initiation of the ongoing rights issue, to 7.86% of the current issued and outstanding shares and votes in PCI Biotech (whereof 4.96% are shares and 2.90% are subscription rights).
Aasen, including close associates, holds 1,720,000 shares and 993,800 subscription rights in PCI Biotech, equal to 10.86% ownership of the current issued and outstanding shares and votes in PCI Biotech (whereof 6.88% are shares and 3,98% are subscription rights).
This notification is based on the share capital of PCI Biotech being NOK 74,984,670 divided on 24,994,890 shares.